ALK and non-small cell lung carcinoma: The Vysis ALK Break Apart FISH Probe Kit, designed to identify ALK-positive NSCLC patients, is approved by the US Food and Drug Administration (FDA) to detect rearrangements of the ALK gene (Pfizer, 2011).